Stephanie Davis
Stock Analyst at Barclays
(1.21)
# 3,624
Out of 4,868 analysts
92
Total ratings
35.38%
Success rate
-14.16%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Equal-Weight | $175 → $185 | $179.43 | +3.10% | 5 | Apr 23, 2025 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $37.69 | +19.40% | 3 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $12.98 | -61.48% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $57.36 | +30.75% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $4.83 | +44.93% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $4.60 | +30.43% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $9.25 | +105.41% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $293.66 | -1.25% | 2 | Nov 7, 2024 | |
| PINC Premier | Maintains: Equal-Weight | $20 → $24 | $22.06 | +8.79% | 3 | Nov 6, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $163.40 | -18.60% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $58 | $28.03 | +106.92% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $2.68 | +11.94% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $261.88 | -4.92% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $26.21 | +10.64% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $6.90 | +392.75% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $20.97 | +62.14% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $280.08 | -16.81% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $3.60 | +372.22% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $101.30 | -24.98% | 5 | Jun 7, 2022 |
Quest Diagnostics
Apr 23, 2025
Maintains: Equal-Weight
Price Target: $175 → $185
Current: $179.43
Upside: +3.10%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $37.69
Upside: +19.40%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $12.98
Upside: -61.48%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $57.36
Upside: +30.75%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $4.83
Upside: +44.93%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $4.60
Upside: +30.43%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $9.25
Upside: +105.41%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $293.66
Upside: -1.25%
Premier
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $22.06
Upside: +8.79%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $163.40
Upside: -18.60%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $28.03
Upside: +106.92%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $2.68
Upside: +11.94%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $261.88
Upside: -4.92%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $26.21
Upside: +10.64%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $6.90
Upside: +392.75%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $20.97
Upside: +62.14%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $280.08
Upside: -16.81%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $3.60
Upside: +372.22%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $101.30
Upside: -24.98%